Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nirogacestat - SpringWorks Therapeutics

Next Previous
X
Search
Drug Profile

Nirogacestat - SpringWorks Therapeutics

Alternative Names: Nirogacestat hydrobromide - SpringWorks Therapeutics; OGSIVEOTM; PF 3084014; PF-03084014; PF-03084014-04

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Janssen Biotech; Pfizer; SpringWorks Therapeutics
  • Class Amides; Amines; Antineoplastics; Fluorine compounds; Imidazoles; Naphthalenes; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibroma; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fibroma
  • Phase II Ovarian cancer
  • Phase I/II Multiple myeloma
  • Discontinued Alzheimer's disease; Pancreatic cancer; Precursor T-cell lymphoblastic leukaemia-lymphoma; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in United Kingdom (PO, Tablet)
  • 01 Mar 2024 Preregistration for Fibroma in European Union (PO)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Belgium (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top